Compare EDIT & IPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDIT | IPI |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.8M | 499.4M |
| IPO Year | 2016 | 2007 |
| Metric | EDIT | IPI |
|---|---|---|
| Price | $3.63 | $33.46 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 5 | 1 |
| Target Price | $5.30 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 2.6M | 239.7K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.50 | ★ 105.14 |
| EPS | N/A | ★ 0.56 |
| Revenue | $31,937,000.00 | ★ $298,328,000.00 |
| Revenue This Year | N/A | $5.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $59.96 |
| Revenue Growth | ★ 132.64 | 17.13 |
| 52 Week Low | $1.66 | $22.55 |
| 52 Week High | $4.54 | $50.34 |
| Indicator | EDIT | IPI |
|---|---|---|
| Relative Strength Index (RSI) | 70.63 | 40.66 |
| Support Level | $2.26 | $33.33 |
| Resistance Level | $3.65 | $35.78 |
| Average True Range (ATR) | 0.24 | 1.40 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 96.99 | 26.68 |
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, where the firm's production facilities are located.